The University of California (“UC”) and The Broad Institute, Inc. (“Broad”) are among the leaders in the development of CRISPR technology. Both UC and Broad filed patent applications for claims broadly drawn to CRISPR-Cas9 systems and methods of DNA editing. These parties are currently engaged in litigation over patents concerning the potentially most lucrative application of CRISPR technology – the use of CRISPR-Cas9 in plant and animal (eukaryotic) cells. The outcome of this litigation will affect control of the CRISPR platform and development of the technology.
The post The CRISPR Tug of War appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Squires Restores PTAB’s RPI Identification Requirement to Exacting Pre-SharkNinja Standard
- Tariffs, Tech Wars, and Patent Turmoil: Navigating IP Strategy in a Rapidly Changing World | IPWatchdog Unleashed
- Life Sciences Masters Panelists Lament Mounting Policy Uncertainty
- Interveners Left Out in the Cold: EPO’s G 2/24 Tightens Rules for Late Parties to Patent Challenges
- Massie to Reintroduce RALIA in Bid to Abolish PTAB